Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-09-25

AUTHORS

Ben Tran, Richard D. Carvajal, Aurelien Marabelle, Sandip Pravin Patel, Patricia M. LoRusso, Erik Rasmussen, Gloria Juan, Vijay V. Upreti, Courtney Beers, Gataree Ngarmchamnanrith, Patrick Schöffski

ABSTRACT

BackgroundThis open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of AMG 228, an agonistic human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor−related protein (GITR), in patients with refractory advanced solid tumors.MethodsAMG 228 was administered intravenously every 3 weeks (Q3W). Dose escalation was in two stages: single-patient cohorts (3, 9, 30, and 90 mg), followed by “rolling six” design (n = 2–6; 180, 360, 600, 900, and 1200 mg). Primary endpoints included incidence of dose-limiting toxicities (DLTs), AEs, and pharmacokinetics. Additional endpoints were objective response and pharmacodynamic response.ResultsThirty patients received AMG 228, which was well tolerated up to the maximum planned dose (1200 mg). No DLTs occurred; the MTD was not reached. The most common treatment-related AEs were fatigue (13%), infusion-related reaction (7%), pyrexia (7%), decreased appetite (7%), and hypophosphatemia (7%). Two patients had binding anti−AMG 228 antibodies (one at baseline); no neutralizing antibodies were detected. AMG 228 exhibited target-mediated drug disposition, and serum exposure was approximately dose proportional at 180–1200 mg and greater than dose proportional at 3–1200 mg. Doses > 360 mg Q3W achieved serum trough coverage for 95% in vitro GITR occupancy. Despite GITR coverage in peripheral blood and tumor biopsies, there was no evidence of T-cell activation or anti-tumor activity.ConclusionsIn patients with advanced solid tumors, AMG 228 Q3W was tolerable up to the highest tested dose (1200 mg), exhibited favorable pharmacokinetics, and provided target coverage indicating a pharmacokinetic profile appropriate for longer intervals. However, there was no evidence of T-cell activation or anti-tumor activity with AMG 228 monotherapy.Trial registrationClinicalTrials.gov, NCT02437916. More... »

PAGES

93

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-018-0407-x

DOI

http://dx.doi.org/10.1186/s40425-018-0407-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107229274

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30253804


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Immunological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucocorticoid-Induced TNFR-Related Protein", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucocorticoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunophenotyping", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenotype", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, 3000, Melbourne, VIC, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, 3000, Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tran", 
        "givenName": "Ben", 
        "id": "sg:person.0717760414.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717760414.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York City, New York, USA", 
          "id": "http://www.grid.ac/institutes/grid.516091.a", 
          "name": [
            "Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York City, New York, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D.", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "INSERM U1015, Gustave Roussy, Villejuif, France", 
          "id": "http://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "D\u00e9partement d\u2019Innovation Th\u00e9rapeutique et d\u2019Essais Pr\u00e9coces, Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France", 
            "INSERM U1015, Gustave Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marabelle", 
        "givenName": "Aurelien", 
        "id": "sg:person.0746230417.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746230417.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Medical Oncology, Moores Cancer Center, University of California San Diego, La Jolla, California, USA", 
          "id": "http://www.grid.ac/institutes/grid.516081.b", 
          "name": [
            "Division of Hematology and Medical Oncology, Moores Cancer Center, University of California San Diego, La Jolla, California, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "Sandip Pravin", 
        "id": "sg:person.01155034725.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155034725.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Yale Cancer Center, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.433818.5", 
          "name": [
            "Department of Medical Oncology, Yale Cancer Center, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "LoRusso", 
        "givenName": "Patricia M.", 
        "id": "sg:person.07606124667.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07606124667.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc, Thousand Oaks, California, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc, Thousand Oaks, California, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rasmussen", 
        "givenName": "Erik", 
        "id": "sg:person.01344356634.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344356634.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc, Thousand Oaks, California, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc, Thousand Oaks, California, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Juan", 
        "givenName": "Gloria", 
        "id": "sg:person.01277630570.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277630570.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc, South San Francisco, California, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc, South San Francisco, California, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Upreti", 
        "givenName": "Vijay V.", 
        "id": "sg:person.01257770507.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257770507.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc, Thousand Oaks, California, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc, Thousand Oaks, California, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beers", 
        "givenName": "Courtney", 
        "id": "sg:person.011057764133.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011057764133.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc, Thousand Oaks, California, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc, Thousand Oaks, California, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ngarmchamnanrith", 
        "givenName": "Gataree", 
        "id": "sg:person.0705602733.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705602733.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.410569.f", 
          "name": [
            "Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sch\u00f6ffski", 
        "givenName": "Patrick", 
        "id": "sg:person.0746717003.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746717003.22"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00262-010-0866-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037129194", 
          "https://doi.org/10.1007/s00262-010-0866-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13045-018-0582-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101542748", 
          "https://doi.org/10.1186/s13045-018-0582-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-09-25", 
    "datePublishedReg": "2018-09-25", 
    "description": "BackgroundThis open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of AMG 228, an agonistic human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor\u2212related protein (GITR), in patients with refractory advanced solid tumors.MethodsAMG 228 was administered intravenously every 3\u00a0weeks (Q3W). Dose escalation was in two stages: single-patient cohorts (3, 9, 30, and 90\u00a0mg), followed by \u201crolling six\u201d design (n\u2009=\u20092\u20136; 180, 360, 600, 900, and 1200\u00a0mg). Primary endpoints included incidence of dose-limiting toxicities (DLTs), AEs, and pharmacokinetics. Additional endpoints were objective response and pharmacodynamic response.ResultsThirty patients received AMG 228, which was well tolerated up to the maximum planned dose (1200\u00a0mg). No DLTs occurred; the MTD was not reached. The most common treatment-related AEs were fatigue (13%), infusion-related reaction (7%), pyrexia (7%), decreased appetite (7%), and hypophosphatemia (7%). Two patients had binding anti\u2212AMG 228 antibodies (one at baseline); no neutralizing antibodies were detected. AMG 228 exhibited target-mediated drug disposition, and serum exposure was approximately dose proportional at 180\u20131200\u00a0mg and greater than dose proportional at 3\u20131200\u00a0mg. Doses >\u2009360\u00a0mg Q3W achieved serum trough coverage for 95% in vitro GITR occupancy. Despite GITR coverage in peripheral blood and tumor biopsies, there was no evidence of T-cell activation or anti-tumor activity.ConclusionsIn patients with advanced solid tumors, AMG 228 Q3W was tolerable up to the highest tested dose (1200\u00a0mg), exhibited favorable pharmacokinetics, and provided target coverage indicating a pharmacokinetic profile appropriate for longer intervals. However, there was no evidence of T-cell activation or anti-tumor activity with AMG 228 monotherapy.Trial registrationClinicalTrials.gov, NCT02437916.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s40425-018-0407-x", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5475983", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "publisher": "BMJ", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "advanced solid tumors", 
      "dose-limiting toxicity", 
      "phase 1 study", 
      "anti-tumor activity", 
      "T cell activation", 
      "solid tumors", 
      "glucocorticoid-induced tumor necrosis factor", 
      "common treatment-related AEs", 
      "refractory advanced solid tumors", 
      "human IgG1 monoclonal antibody", 
      "single-patient cohorts", 
      "treatment-related AEs", 
      "infusion-related reactions", 
      "tumor necrosis factor", 
      "target-mediated drug disposition", 
      "dose-escalation results", 
      "IgG1 monoclonal antibody", 
      "ResultsThirty patients", 
      "ConclusionsIn patients", 
      "primary endpoint", 
      "objective response", 
      "dose escalation", 
      "peripheral blood", 
      "pharmacodynamic response", 
      "necrosis factor", 
      "tumor biopsies", 
      "favorable pharmacokinetics", 
      "pharmacokinetic profile", 
      "patients", 
      "Additional endpoints", 
      "serum exposure", 
      "drug disposition", 
      "monoclonal antibodies", 
      "pharmacokinetics", 
      "dose", 
      "tumors", 
      "target coverage", 
      "q3w", 
      "antibodies", 
      "longer intervals", 
      "endpoint", 
      "activation", 
      "monotherapy", 
      "pyrexia", 
      "hypophosphatemia", 
      "biopsy", 
      "BackgroundThis", 
      "humans", 
      "pharmacodynamics", 
      "cohort", 
      "incidence", 
      "MTD", 
      "doses", 
      "blood", 
      "appetite", 
      "weeks", 
      "response", 
      "evidence", 
      "activity", 
      "study", 
      "toxicity", 
      "exposure", 
      "escalation", 
      "safety", 
      "fatigue", 
      "interval", 
      "disposition", 
      "factors", 
      "protein", 
      "coverage", 
      "Ae", 
      "profile", 
      "stage", 
      "results", 
      "reaction", 
      "occupancy", 
      "design", 
      "maximum", 
      "AES"
    ], 
    "name": "Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor\u2013related protein agonist AMG 228 in patients with advanced solid tumors", 
    "pagination": "93", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107229274"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-018-0407-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30253804"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-018-0407-x", 
      "https://app.dimensions.ai/details/publication/pub.1107229274"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_763.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s40425-018-0407-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0407-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0407-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0407-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0407-x'


 

This table displays all metadata directly associated to this object as RDF triples.

300 TRIPLES      21 PREDICATES      121 URIs      111 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-018-0407-x schema:about N019d97d538f444838b60be8bd98459ef
2 N11895a13b3034da7b0ee2d33a6d22fbf
3 N2b96f5423a5d4a22936697ca6a9af51d
4 N2e70b279d89945c5b28a0300854bc01c
5 N45ee2d6a9c814b10866f0e53424468ca
6 N5b4bc018150445aa88d2f73d60ffbaa1
7 N6ac78d63088d4ac8b47500e7ed14febc
8 N8d825d0614dc4aa79fd0923a41ea08df
9 N939a2589bd574fa18dc8258832d1daae
10 Nb5c5ac6cf286473eb5d9dd568cfca172
11 Ncc8d7358809d4edcafa7d30a866d36c6
12 Nd2a449ea5b354df787dcb5fe4bc43d16
13 Nd7d87decd1254cce9e4ec9ba2e078dd4
14 Ndc69d964c78d4d21aaa75eef832d4ef5
15 Ne260335f96d04b9fbf6ed6680eb777c1
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N4b8d90286bd84232a0ac86e5e5d2ffbf
19 schema:citation sg:pub.10.1007/s00262-010-0866-5
20 sg:pub.10.1186/s13045-018-0582-8
21 schema:datePublished 2018-09-25
22 schema:datePublishedReg 2018-09-25
23 schema:description BackgroundThis open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of AMG 228, an agonistic human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor−related protein (GITR), in patients with refractory advanced solid tumors.MethodsAMG 228 was administered intravenously every 3 weeks (Q3W). Dose escalation was in two stages: single-patient cohorts (3, 9, 30, and 90 mg), followed by “rolling six” design (n = 2–6; 180, 360, 600, 900, and 1200 mg). Primary endpoints included incidence of dose-limiting toxicities (DLTs), AEs, and pharmacokinetics. Additional endpoints were objective response and pharmacodynamic response.ResultsThirty patients received AMG 228, which was well tolerated up to the maximum planned dose (1200 mg). No DLTs occurred; the MTD was not reached. The most common treatment-related AEs were fatigue (13%), infusion-related reaction (7%), pyrexia (7%), decreased appetite (7%), and hypophosphatemia (7%). Two patients had binding anti−AMG 228 antibodies (one at baseline); no neutralizing antibodies were detected. AMG 228 exhibited target-mediated drug disposition, and serum exposure was approximately dose proportional at 180–1200 mg and greater than dose proportional at 3–1200 mg. Doses > 360 mg Q3W achieved serum trough coverage for 95% in vitro GITR occupancy. Despite GITR coverage in peripheral blood and tumor biopsies, there was no evidence of T-cell activation or anti-tumor activity.ConclusionsIn patients with advanced solid tumors, AMG 228 Q3W was tolerable up to the highest tested dose (1200 mg), exhibited favorable pharmacokinetics, and provided target coverage indicating a pharmacokinetic profile appropriate for longer intervals. However, there was no evidence of T-cell activation or anti-tumor activity with AMG 228 monotherapy.Trial registrationClinicalTrials.gov, NCT02437916.
24 schema:genre article
25 schema:isAccessibleForFree true
26 schema:isPartOf N912b315ff85145649453e04632613480
27 N98de7b75897a43699b6fcb39e21a8620
28 sg:journal.1049249
29 schema:keywords AES
30 Additional endpoints
31 Ae
32 BackgroundThis
33 ConclusionsIn patients
34 IgG1 monoclonal antibody
35 MTD
36 ResultsThirty patients
37 T cell activation
38 activation
39 activity
40 advanced solid tumors
41 anti-tumor activity
42 antibodies
43 appetite
44 biopsy
45 blood
46 cohort
47 common treatment-related AEs
48 coverage
49 design
50 disposition
51 dose
52 dose escalation
53 dose-escalation results
54 dose-limiting toxicity
55 doses
56 drug disposition
57 endpoint
58 escalation
59 evidence
60 exposure
61 factors
62 fatigue
63 favorable pharmacokinetics
64 glucocorticoid-induced tumor necrosis factor
65 human IgG1 monoclonal antibody
66 humans
67 hypophosphatemia
68 incidence
69 infusion-related reactions
70 interval
71 longer intervals
72 maximum
73 monoclonal antibodies
74 monotherapy
75 necrosis factor
76 objective response
77 occupancy
78 patients
79 peripheral blood
80 pharmacodynamic response
81 pharmacodynamics
82 pharmacokinetic profile
83 pharmacokinetics
84 phase 1 study
85 primary endpoint
86 profile
87 protein
88 pyrexia
89 q3w
90 reaction
91 refractory advanced solid tumors
92 response
93 results
94 safety
95 serum exposure
96 single-patient cohorts
97 solid tumors
98 stage
99 study
100 target coverage
101 target-mediated drug disposition
102 toxicity
103 treatment-related AEs
104 tumor biopsies
105 tumor necrosis factor
106 tumors
107 weeks
108 schema:name Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
109 schema:pagination 93
110 schema:productId N15e4a1a043e04e3a9bc6df9d7bac3015
111 N51698f58438246a5a5b58c169dcf936e
112 Nc0f5b3015c5e45cb92068d253bd35d48
113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107229274
114 https://doi.org/10.1186/s40425-018-0407-x
115 schema:sdDatePublished 2022-12-01T06:37
116 schema:sdLicense https://scigraph.springernature.com/explorer/license/
117 schema:sdPublisher Ncc6c1976374e45c2a037eb856a278514
118 schema:url https://doi.org/10.1186/s40425-018-0407-x
119 sgo:license sg:explorer/license/
120 sgo:sdDataset articles
121 rdf:type schema:ScholarlyArticle
122 N019d97d538f444838b60be8bd98459ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Cell Line, Tumor
124 rdf:type schema:DefinedTerm
125 N0b0b55f8466b470587552b96ed1cf262 rdf:first sg:person.01344356634.28
126 rdf:rest N7650b90e83a54b0d900080535c3b171b
127 N11895a13b3034da7b0ee2d33a6d22fbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Neoplasm Staging
129 rdf:type schema:DefinedTerm
130 N15e4a1a043e04e3a9bc6df9d7bac3015 schema:name doi
131 schema:value 10.1186/s40425-018-0407-x
132 rdf:type schema:PropertyValue
133 N1ad514428c40453ba0a6f1d7aea1f002 rdf:first sg:person.0746230417.54
134 rdf:rest N793f0dfef13a4684806c17abfc77c307
135 N2b96f5423a5d4a22936697ca6a9af51d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Glucocorticoid-Induced TNFR-Related Protein
137 rdf:type schema:DefinedTerm
138 N2e70b279d89945c5b28a0300854bc01c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Neoplasms
140 rdf:type schema:DefinedTerm
141 N45ee2d6a9c814b10866f0e53424468ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Middle Aged
143 rdf:type schema:DefinedTerm
144 N4b8d90286bd84232a0ac86e5e5d2ffbf rdf:first sg:person.0717760414.82
145 rdf:rest N6c07bc981d82419c8cd78cb940cd7c0e
146 N51698f58438246a5a5b58c169dcf936e schema:name dimensions_id
147 schema:value pub.1107229274
148 rdf:type schema:PropertyValue
149 N5b4bc018150445aa88d2f73d60ffbaa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Humans
151 rdf:type schema:DefinedTerm
152 N65e9e0df3e684f2aa70dc505646aca43 rdf:first sg:person.07606124667.43
153 rdf:rest N0b0b55f8466b470587552b96ed1cf262
154 N6ac78d63088d4ac8b47500e7ed14febc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Male
156 rdf:type schema:DefinedTerm
157 N6c07bc981d82419c8cd78cb940cd7c0e rdf:first sg:person.0726366600.25
158 rdf:rest N1ad514428c40453ba0a6f1d7aea1f002
159 N7650b90e83a54b0d900080535c3b171b rdf:first sg:person.01277630570.12
160 rdf:rest N7821fcb142924c7b97202bc22d921b85
161 N7821fcb142924c7b97202bc22d921b85 rdf:first sg:person.01257770507.59
162 rdf:rest Nfc8a59e76e5b4f79b646af63320e4527
163 N793f0dfef13a4684806c17abfc77c307 rdf:first sg:person.01155034725.54
164 rdf:rest N65e9e0df3e684f2aa70dc505646aca43
165 N7fc85a84ad9240b29f4e09a2060cacaa rdf:first sg:person.0705602733.63
166 rdf:rest N81a187c7ea444d6bb8ee47c2160aed6d
167 N81a187c7ea444d6bb8ee47c2160aed6d rdf:first sg:person.0746717003.22
168 rdf:rest rdf:nil
169 N8d825d0614dc4aa79fd0923a41ea08df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Aged, 80 and over
171 rdf:type schema:DefinedTerm
172 N912b315ff85145649453e04632613480 schema:volumeNumber 6
173 rdf:type schema:PublicationVolume
174 N939a2589bd574fa18dc8258832d1daae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Female
176 rdf:type schema:DefinedTerm
177 N98de7b75897a43699b6fcb39e21a8620 schema:issueNumber 1
178 rdf:type schema:PublicationIssue
179 Nb5c5ac6cf286473eb5d9dd568cfca172 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Immunophenotyping
181 rdf:type schema:DefinedTerm
182 Nc0f5b3015c5e45cb92068d253bd35d48 schema:name pubmed_id
183 schema:value 30253804
184 rdf:type schema:PropertyValue
185 Ncc6c1976374e45c2a037eb856a278514 schema:name Springer Nature - SN SciGraph project
186 rdf:type schema:Organization
187 Ncc8d7358809d4edcafa7d30a866d36c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Biomarkers
189 rdf:type schema:DefinedTerm
190 Nd2a449ea5b354df787dcb5fe4bc43d16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Antineoplastic Agents, Immunological
192 rdf:type schema:DefinedTerm
193 Nd7d87decd1254cce9e4ec9ba2e078dd4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Glucocorticoids
195 rdf:type schema:DefinedTerm
196 Ndc69d964c78d4d21aaa75eef832d4ef5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Phenotype
198 rdf:type schema:DefinedTerm
199 Ne260335f96d04b9fbf6ed6680eb777c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Aged
201 rdf:type schema:DefinedTerm
202 Nfc8a59e76e5b4f79b646af63320e4527 rdf:first sg:person.011057764133.55
203 rdf:rest N7fc85a84ad9240b29f4e09a2060cacaa
204 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
205 schema:name Medical and Health Sciences
206 rdf:type schema:DefinedTerm
207 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
208 schema:name Oncology and Carcinogenesis
209 rdf:type schema:DefinedTerm
210 sg:grant.5475983 http://pending.schema.org/fundedItem sg:pub.10.1186/s40425-018-0407-x
211 rdf:type schema:MonetaryGrant
212 sg:journal.1049249 schema:issn 2051-1426
213 schema:name Journal for ImmunoTherapy of Cancer
214 schema:publisher BMJ
215 rdf:type schema:Periodical
216 sg:person.011057764133.55 schema:affiliation grid-institutes:grid.417886.4
217 schema:familyName Beers
218 schema:givenName Courtney
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011057764133.55
220 rdf:type schema:Person
221 sg:person.01155034725.54 schema:affiliation grid-institutes:grid.516081.b
222 schema:familyName Patel
223 schema:givenName Sandip Pravin
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155034725.54
225 rdf:type schema:Person
226 sg:person.01257770507.59 schema:affiliation grid-institutes:grid.417886.4
227 schema:familyName Upreti
228 schema:givenName Vijay V.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257770507.59
230 rdf:type schema:Person
231 sg:person.01277630570.12 schema:affiliation grid-institutes:grid.417886.4
232 schema:familyName Juan
233 schema:givenName Gloria
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277630570.12
235 rdf:type schema:Person
236 sg:person.01344356634.28 schema:affiliation grid-institutes:grid.417886.4
237 schema:familyName Rasmussen
238 schema:givenName Erik
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344356634.28
240 rdf:type schema:Person
241 sg:person.0705602733.63 schema:affiliation grid-institutes:grid.417886.4
242 schema:familyName Ngarmchamnanrith
243 schema:givenName Gataree
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705602733.63
245 rdf:type schema:Person
246 sg:person.0717760414.82 schema:affiliation grid-institutes:grid.1055.1
247 schema:familyName Tran
248 schema:givenName Ben
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717760414.82
250 rdf:type schema:Person
251 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.516091.a
252 schema:familyName Carvajal
253 schema:givenName Richard D.
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
255 rdf:type schema:Person
256 sg:person.0746230417.54 schema:affiliation grid-institutes:grid.14925.3b
257 schema:familyName Marabelle
258 schema:givenName Aurelien
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746230417.54
260 rdf:type schema:Person
261 sg:person.0746717003.22 schema:affiliation grid-institutes:grid.410569.f
262 schema:familyName Schöffski
263 schema:givenName Patrick
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746717003.22
265 rdf:type schema:Person
266 sg:person.07606124667.43 schema:affiliation grid-institutes:grid.433818.5
267 schema:familyName LoRusso
268 schema:givenName Patricia M.
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07606124667.43
270 rdf:type schema:Person
271 sg:pub.10.1007/s00262-010-0866-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037129194
272 https://doi.org/10.1007/s00262-010-0866-5
273 rdf:type schema:CreativeWork
274 sg:pub.10.1186/s13045-018-0582-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101542748
275 https://doi.org/10.1186/s13045-018-0582-8
276 rdf:type schema:CreativeWork
277 grid-institutes:grid.1055.1 schema:alternateName Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, 3000, Melbourne, VIC, Australia
278 schema:name Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, 3000, Melbourne, VIC, Australia
279 rdf:type schema:Organization
280 grid-institutes:grid.14925.3b schema:alternateName INSERM U1015, Gustave Roussy, Villejuif, France
281 schema:name Département d’Innovation Thérapeutique et d’Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France
282 INSERM U1015, Gustave Roussy, Villejuif, France
283 rdf:type schema:Organization
284 grid-institutes:grid.410569.f schema:alternateName Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium
285 schema:name Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium
286 rdf:type schema:Organization
287 grid-institutes:grid.417886.4 schema:alternateName Amgen Inc, South San Francisco, California, USA
288 Amgen Inc, Thousand Oaks, California, USA
289 schema:name Amgen Inc, South San Francisco, California, USA
290 Amgen Inc, Thousand Oaks, California, USA
291 rdf:type schema:Organization
292 grid-institutes:grid.433818.5 schema:alternateName Department of Medical Oncology, Yale Cancer Center, New Haven, CT, USA
293 schema:name Department of Medical Oncology, Yale Cancer Center, New Haven, CT, USA
294 rdf:type schema:Organization
295 grid-institutes:grid.516081.b schema:alternateName Division of Hematology and Medical Oncology, Moores Cancer Center, University of California San Diego, La Jolla, California, USA
296 schema:name Division of Hematology and Medical Oncology, Moores Cancer Center, University of California San Diego, La Jolla, California, USA
297 rdf:type schema:Organization
298 grid-institutes:grid.516091.a schema:alternateName Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York City, New York, USA
299 schema:name Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York City, New York, USA
300 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...